What diseases is Deuterocolexitinib/Sondido mainly used to treat?

Deucravacitinib has quickly become an important innovative drug in the field of plaque psoriasis since its launch. Its clinical application value is mainly reflected in the balance between oral convenience and lasting efficacy. For patients with moderate to severe plaque psoriasis, they used to rely on traditional oral drugs or injectable biologics. As the first selective TYK2 inhibitor, deuterated colexitinib provides patients with a new model of controlling the disease by taking it orally once a day. This convenience not only improves compliance, but also allows more patients to adhere to treatment over the long term.

By 2025, the price trend of deuterated coxitinib will become a topic of widespread concern among patients and doctors. According to the current situation, China's original version has been launched and included in medical insurance. The price of 6 mg 7 tablets is about more than 1,000 yuan. After medical insurance payment, the patient's out-of-pocket burden is significantly reduced. The price of the original research version of 6 mg 30 tablets in the U.S. market is still around US$50,000. Affected by exchange rates and regional differences, there are obvious differences in accessibility to international patients.

It is worth noting that generic versions have been launched in Laos, Bangladesh and other countries, and the ingredients are consistent with the original drug.The price of 6mg*30 tablets is about four to five hundred yuan. Although the compliance and quality supervision of generic drugs in some markets require more attention, they undoubtedly provide more affordable options for patients with greater financial pressure. With the expiration of patents and global production expansion, the overall price of deuterated colexitinib is expected to gradually decrease in 2025, especially in the Asia-Pacific market, where patient access will become more diversified.

In the future, the application fields of deuterated colexitinib may be further expanded, such as clinical research in psoriatic arthritis and systemic lupus erythematosus. If new indications are approved, its market demand will continue to expand. In terms of price, medical insurance coverage and international generic drug competition will be the key factors that determine patient burden.

Reference materials:https://go.drugbank.com/drugs/DB16650